We are live on ! Find out more
CERE

Cerevel Therapeutics Holdings, Inc. Common Stock
CERE

Delisted

CERE was delisted on the 31st of July, 2024.

Back to rankings

195 hedge funds and large institutions have $6.64B invested in Cerevel Therapeutics Holdings, Inc. Common Stock in 2023 Q4 according to their latest regulatory filings, with 91 funds opening new positions, 61 increasing their positions, 33 reducing their positions, and 15 closing their positions.

New
Increased
Maintained
Reduced
Closed

507% more first-time investments, than exits

New positions opened: 91 | Existing positions closed: 15

175% more funds holding in top 10

Funds holding in top 10: 4 → 11 (+7)

116% more capital invested

Capital invested by funds: $3.07B → $6.64B (+$3.57B)

85% more repeat investments, than reductions

Existing positions increased: 61 | Existing positions reduced: 33

64% more funds holding

Funds holding: 119 → 195 (+76)

3% more call options, than puts

Call options by funds: $79.6M | Put options by funds: $77.1M

Holders
195
Holders Change
+76
Holders Change %
+63.87%
% of All Funds
2.84%
Holding in Top 10
11
Holding in Top 10 Change
+7
Holding in Top 10 Change %
+175%
% of All Funds
0.16%
New
91
Increased
61
Reduced
33
Closed
15
Calls
$79.6M
Puts
$77.1M
Net Calls
+$2.49M
Net Calls Change
+$1.82M

Top Buyers

1
ACA
Avoro Capital Advisors
New York
+$190M
2
BCI
Bain Capital Investors
Massachusetts
+$157M
3
Fidelity International
Fidelity International
Bermuda
+$79.5M
4
Balyasny Asset Management
Balyasny Asset Management
Illinois
+$54.9M
5
UOC
UBS O'Connor
Illinois
+$49.6M

Top Sellers

1
Fidelity Investments
Fidelity Investments
Massachusetts
-$400M
2
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$137M
3
AG
Artal Group
Luxembourg
-$46.9M
4
T. Rowe Price Investment Management
T. Rowe Price Investment Management
Maryland
-$39.8M
5
Millennium Management
Millennium Management
New York
-$29.3M
Name Holding Trade Value Shares
Change 		Change in
Stake
BCI
1
Bain Capital Investors
Massachusetts
$2.78B +$157M +5,480,052 +9%
PA
2
Perceptive Advisors
New York
$465M +$25.2M +876,808 +9%
Fidelity Investments
3
Fidelity Investments
Massachusetts
$411M -$400M -13,931,293 -59%
ACA
4
Avoro Capital Advisors
New York
$320M +$190M +6,600,000 +691%
Vanguard Group
5
Vanguard Group
Pennsylvania
$313M +$28.8M +1,003,594 +16%
BlackRock
6
BlackRock
New York
$256M +$29.8M +1,036,499 +21%
State Street
7
State Street
Massachusetts
$121M -$1.39M -48,516 -2%
Fidelity International
8
Fidelity International
Bermuda
$117M +$79.5M +2,766,000 New
RSCM
9
Rock Springs Capital Management
Maryland
$113M +$4.17M +145,129 +6%
PBA
10
Paradigm Biocapital Advisors
New York
$98.8M -$5.82M -202,464 -8%
Balyasny Asset Management
11
Balyasny Asset Management
Illinois
$82.3M +$54.9M +1,911,419 +6,415%
Geode Capital Management
12
Geode Capital Management
Massachusetts
$75.9M +$10.1M +350,025 +24%
UOC
13
UBS O'Connor
Illinois
$73.1M +$49.6M +1,725,000 New
AAM
14
Alpine Associates Management
Florida
$69.7M +$47.2M +1,644,100 New
BBA
15
Baker Bros. Advisors
New York
$67.8M +$46M +1,600,000 New
Morgan Stanley
16
Morgan Stanley
New York
$64.1M +$41M +1,428,265 +1,708%
AllianceBernstein
17
AllianceBernstein
Tennessee
$48M +$29.9M +1,042,100 +1,151%
Millennium Management
18
Millennium Management
New York
$47.1M -$29.3M -1,018,701 -48%
PCM
19
Pentwater Capital Management
Florida
$46.6M +$31.6M +1,100,000 New
MF
20
Magnetar Financial
Illinois
$43.2M +$29.3M +1,018,428 New
AA
21
AQR Arbitrage
Connecticut
$39.6M +$26.8M +933,764 New
Voloridge Investment Management
22
Voloridge Investment Management
Florida
$38.2M +$25.9M +900,024 New
Capital International Investors
23
Capital International Investors
California
$36.6M +$24.8M +863,786 New
Westfield Capital Management
24
Westfield Capital Management
Massachusetts
$33.3M -$5.43M -188,989 -19%
AAA
25
Affinity Asset Advisors
New York
$31.8M +$1.87M +64,939 +9%
1
2 3 4 5

CERE Hedge Fund Activity: Q4 2023 in Review

195 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Cerevel Therapeutics Holdings, Inc. Common Stock (CERE) for Q4 2023, worth a combined $6.64B — up 116% from $3.07B a quarter earlier.

Buyers outnumbered sellers: 91 funds opened new CERE positions and 15 closed out — a net gain of 76 holders — while 61 added to existing stakes and 33 trimmed.

The largest buyer was Avoro Capital Advisors, adding an estimated $190M. The largest seller was Fidelity Investments, cutting an estimated $400M.

  • 195 institutional investors held Cerevel Therapeutics Holdings, Inc. Common Stock (CERE) as of Q4 2023, up from 119 in Q3 2023.
  • Funds reported $6.64B of Cerevel Therapeutics Holdings, Inc. Common Stock stock for Q4 2023, up 116% quarter-over-quarter.
  • 91 funds opened new Cerevel Therapeutics Holdings, Inc. Common Stock positions in Q4 2023 and 15 closed out, a net change of +76 holders.
  • The largest Cerevel Therapeutics Holdings, Inc. Common Stock buyer in Q4 2023 was Avoro Capital Advisors, an estimated $190M added.
  • The largest Cerevel Therapeutics Holdings, Inc. Common Stock seller in Q4 2023 was Fidelity Investments, an estimated $400M sold.

Based on aggregated 13F filings for Q4 2023.